Switch theme
Sign up to access all valuation multiples
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. It leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. Unlike DNA, mRNA degrades naturally over time without integrating into the cell’s genetic material.
2007
38
LTM Revenue $31.6M
LTM EBITDA n/a
$208M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Cartesian Therapeutics has a last 12-month revenue of $31.6M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Cartesian Therapeutics achieved revenue of $38.9M and an EBITDA of -$76.0M.
Cartesian Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Cartesian Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $26.0M | $38.9M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$235M | -$76.0M | XXX | XXX | XXX |
| EBITDA Margin | -904% | -195% | XXX | XXX | XXX |
| Net Profit | $35.4M | -$220M | XXX | XXX | XXX |
| Net Margin | 136% | -565% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of March 17, 2025, Cartesian Therapeutics's stock price is $16.
Cartesian Therapeutics has current market cap of $406M, and EV of $208M.
See Cartesian Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $208M | $406M | XXX | XXX | XXX | XXX | $-4.17 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of March 17, 2025, Cartesian Therapeutics has market cap of $406M and EV of $208M.
Cartesian Therapeutics's trades at 6.6x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Cartesian Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Cartesian Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $208M | XXX | XXX | XXX |
| EV/Revenue | 5.3x | XXX | XXX | XXX |
| EV/EBITDA | -2.7x | XXX | XXX | XXX |
| P/E | -5.2x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -6.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpCartesian Therapeutics's NTM/LTM revenue growth is -91%
Cartesian Therapeutics's revenue per employee for the last fiscal year averaged $1.0M, while opex per employee averaged $2.0M for the same period.
Over next 12 months, Cartesian Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Cartesian Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Cartesian Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 50% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -195% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -68% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -286% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $1.0M | XXX | XXX | XXX | XXX |
| Opex per Employee | $2.0M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 77% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 116% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 193% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cartesian Therapeutics acquired XXX companies to date.
Last acquisition by Cartesian Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Cartesian Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Cartesian Therapeutics founded? | Cartesian Therapeutics was founded in 2007. |
| Where is Cartesian Therapeutics headquartered? | Cartesian Therapeutics is headquartered in United States of America. |
| How many employees does Cartesian Therapeutics have? | As of today, Cartesian Therapeutics has 38 employees. |
| Who is the CEO of Cartesian Therapeutics? | Cartesian Therapeutics's CEO is Dr. Carsten Brunn, PhD. |
| Is Cartesian Therapeutics publicy listed? | Yes, Cartesian Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Cartesian Therapeutics? | Cartesian Therapeutics trades under RNAC ticker. |
| When did Cartesian Therapeutics go public? | Cartesian Therapeutics went public in 2016. |
| Who are competitors of Cartesian Therapeutics? | Similar companies to Cartesian Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Cartesian Therapeutics? | Cartesian Therapeutics's current market cap is $406M |
| What is the current revenue of Cartesian Therapeutics? | Cartesian Therapeutics's last 12-month revenue is $31.6M. |
| What is the current EV/Revenue multiple of Cartesian Therapeutics? | Current revenue multiple of Cartesian Therapeutics is 6.6x. |
| What is the current revenue growth of Cartesian Therapeutics? | Cartesian Therapeutics revenue growth between 2023 and 2024 was 50%. |
| Is Cartesian Therapeutics profitable? | Yes, Cartesian Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
